<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id>
<journal-title>Frontiers in Cell and Developmental Biology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell Dev. Biol.</abbrev-journal-title>
<issn pub-type="epub">2296-634X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fcell.2021.646774</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cell and Developmental Biology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>CRISPR-cas9 Screening Identified Lethal Genes Enriched in Cell Cycle Pathway and of Prognosis Significance in Breast Cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Sun</surname> <given-names>Xi</given-names></name>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1163368/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Zheng</given-names></name>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/848202/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Chen</surname> <given-names>Xiaosong</given-names></name>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/772133/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Shen</surname> <given-names>Kunwei</given-names></name>
<xref ref-type="corresp" rid="c002"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/950176/overview"/>
</contrib>
</contrib-group>
<aff><institution>Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Mingyan Zhu, Affiliated Hospital of Nantong University, China</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Shang Xie, Peking University, China; Xinxiang Li, Fudan University, China</p></fn>
<corresp id="c001">&#x002A;Correspondence: Kunwei Shen, <email>kwshen@medmail.com.cn</email></corresp>
<corresp id="c002">Xiaosong Chen, <email>chenxiaosong0156@hotmail.com</email></corresp>
<fn fn-type="other" id="fn002"><p><sup>&#x2020;</sup>These authors have contributed equally to this work and share first authorship</p></fn>
<fn fn-type="other" id="fn004"><p>This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Cell and Developmental Biology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>19</day>
<month>03</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>9</volume>
<elocation-id>646774</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>12</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>02</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2021 Sun, Wang, Chen and Shen.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Sun, Wang, Chen and Shen</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<sec><title>Background</title><p>Lethal genes have not been systematically analyzed in breast cancer which may have significant prognostic value. The current study aims to investigate vital genes related to cell viability by analyzing the CRISPR-cas9 screening data, which may provide novel therapeutic target for patients.</p></sec>
<sec><title>Methods</title><p>Genes differentially expressed between tumor and normal tissue from the Cancer Genome Atlas (TCGA) and genes related to cell viability by CRISPR-cas9 screening from Depmap (Cancer Dependency Map) were overlapped. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analysis was conducted to identify which pathways of overlapped genes were enriched. GSE21653 set was randomized into training and internal validation dataset at a ratio of 3:1, and external validation was performed in GSE20685 set. The least absolute shrinkage and selection operator (LASSO) regression was used to construct a signature to predict recurrence-free survival (RFS) of breast cancer patients. Univariate and multivariate Cox regression were used to evaluate the prognostic value of this signature. Differentially expressed genes (DEGs) between high-risk and low-risk patients were then analyzed to identify the main pathways regulated by this signature. Weighted correlation network analysis (WGCNA) was conducted to recognize modules correlated with high risk. Enrichment analysis was then used to identify pathways regulated by genes shared in the overlapped genes, DEGs, and WGCNA.</p></sec>
<sec><title>Results</title><p>A total of 86 oncogenes were upregulated in TCGA database and overlapped with lethal genes in Depmap database, which were enriched in cell cycle pathway. A total of 51 genes were included in the gene signature based on LASSO regression, and the median risk score of 2.36 was used as cut-off to separate low-risk patients from high-risk patients. High-risk patients showed worse RFS compared with low-risk patients in internal training, internal validation, and external validation dataset. Time-dependent receiver operating characteristic curves of 3 and 5 years indicated that risk score was superior to tumor stage, age, and PAM50 in both entire and external validation datasets. Cell cycle was the main different pathway between the high-risk and low-risk groups. Meanwhile, cell cycle was also the main pathway enriched in the 25 genes which were shared among 86 genes, DEGs, and WGCNA.</p></sec>
<sec><title>Conclusion</title><p>Cell cycle pathway, identified by CRISPR-cas9 screening, was a key pathway regulating cell viability, which has significant prognostic values and can serve as a new target for breast cancer patient treatment.</p></sec>
</abstract>
<kwd-group>
<kwd>CRISPR-cas9 screening</kwd>
<kwd>breast cancer</kwd>
<kwd>cell cycle</kwd>
<kwd>signature</kwd>
<kwd>cell viability</kwd>
</kwd-group>
<counts>
<fig-count count="8"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="35"/>
<page-count count="11"/>
<word-count count="0"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1">
<title>Introduction</title>
<p>Breast cancer, with the highest incidence rate among female cancer, is the second leading cause of cancer-related death and poses a great threat to women&#x2019;s health (<xref ref-type="bibr" rid="B25">Siegel et al., 2020</xref>). It accounts for 30% of all new cases and is responsible for 15% of cancer deaths in women. Despite that the prognosis of patients has been improving over the past few years, the complex biological behaviors of breast cancer still hamper the progress in clinical treatment. Thus, understanding the specific vulnerability of breast carcinoma is of great importance.</p>
<p>Currently, CRISPR-cas9 screening is emerging as a powerful tool for precise medicine (<xref ref-type="bibr" rid="B4">Doudna and Charpentier, 2014</xref>; <xref ref-type="bibr" rid="B17">Kurata et al., 2018</xref>). Combining cas9 with pooled guide RNA libraries facilitates screening of genes that contribute to specific biologic phenotypes and diseases in a high-throughput way (<xref ref-type="bibr" rid="B12">Joung et al., 2017</xref>). This &#x201C;phenotype-to-genotype&#x201D; approach includes modifying expression of genes, selecting cells with a phenotype of interest, and sequencing the perturbation of interest, which allows for discovering genes related to cell viability (<xref ref-type="bibr" rid="B24">Schuster et al., 2019</xref>). Meanwhile, large-scale loss-of-function screening for cancer dependences have been performed in a variety of well-characterized cancer cell lines to assess the effect of single-gene knockout on cell viability (<xref ref-type="bibr" rid="B22">Meyers et al., 2017</xref>; <xref ref-type="bibr" rid="B32">Tsherniak et al., 2017</xref>). These data were deposited in the Cancer Dependence Map (DepMap) website.</p>
<p>Aberrant cell cycle is a hallmark of cancer (<xref ref-type="bibr" rid="B10">Hanahan and Weinberg, 2011</xref>). The evolution of cell cycle is conservative. Checkpoints have evolved to ensure that cell cycle progress is under sequential activation (<xref ref-type="bibr" rid="B14">Kastan and Bartek, 2004</xref>; <xref ref-type="bibr" rid="B27">Strzyz, 2016</xref>). Under the stimulation of mitogenic signal, cyclin-dependent kinases (CDKs) associate with cyclins and phosphorylate intracellular proteins that orchestrate cell cycle progress in a well-organized way (<xref ref-type="bibr" rid="B21">Malumbres and Barbacid, 2009</xref>; <xref ref-type="bibr" rid="B20">Malumbres, 2014</xref>). In cancer cells, aberrant signals are developed and promote the activation of CDK&#x2013;cyclin complex. Deregulation of the cell cycle engine eventually leads to uncontrolled cell proliferation and genomic instability in cancer. Thus, the therapeutic potential of targeting the cell cycle has been increasingly concerned (<xref ref-type="bibr" rid="B19">Lim and Kaldis, 2013</xref>). In breast cancer, the application of CDK4/6 inhibitor transformed treatment landscape in estrogen (ER)-positive human epidermal growth factor receptor-2 (HER2) negative breast cancer. The improvement in prognosis indicated that targeting cell cycle is an essential way to cancer treatment (<xref ref-type="bibr" rid="B11">Ingham and Schwartz, 2017</xref>; <xref ref-type="bibr" rid="B26">Slamon et al., 2018</xref>; <xref ref-type="bibr" rid="B31">Tripathy et al., 2018</xref>).</p>
<p>Biological process involving cell viability is complex. However, cell vulnerability of breast cancer has not been systematically researched. Meanwhile, pathways and the prognostic significance of these genes have never been detailed. In the current study, we aimed to identify genes differentially expressed in tumor tissues and contributed to cell viability. Using these genes, a prediction model with prognostic significance was constructed and validated. The pathways and biological processes regulated by these genes were also evaluated.</p>
</sec>
<sec id="S2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="S2.SS1">
<title>Identification of Viability Vulnerable</title>
<p>Dependence scores of breast cancer cell lines were downloaded from the Depmap dataset<sup><xref ref-type="fn" rid="footnote1">1</xref></sup>, and this is the result from a series of loss-of-function genomic screening in different cell lines. Dependence score was calculated by CERES algorithm to identify genes essential to proliferation and survival (<xref ref-type="bibr" rid="B22">Meyers et al., 2017</xref>). A negative score of a gene indicates that knocking out of the gene inhibits the survival of a cell line, whereas a positive score indicates that knocking out of the gene promotes the survival and proliferation. Cut-offs of 0.5 and &#x2212;0.5 were to define growth-suppressing genes and growth-promoting genes.</p>
<p>Read counts of breast cancer were downloaded from TCGA datasets<sup><xref ref-type="fn" rid="footnote2">2</xref></sup>. Differentially expressed genes between tumor and normal patients were calculated based on the negative binomial distribution using DESeq2 package. Adjusted <italic>p</italic> value &#x003C;0.05 and absolute fold change greater than 2 were used as cut-off to select differentially expressed genes. Growth-suppressing genes from Depmap were overlapped with downregulated genes from the TCGA dataset, and growth-promoting genes from Depmap were overlapped with upregulated genes from the TCGA dataset to select genes for further analysis.</p>
</sec>
<sec id="S2.SS2">
<title>Data Processing</title>
<p>Raw data of GSE20685 and GSE21653 were downloaded from the GEO database<sup><xref ref-type="fn" rid="footnote3">3</xref></sup>. These two datasets were both from [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 platform. The raw data of GSE20685 and GSE21653 were normalized by gcrma algorithm simultaneously. The probe ID was converted into gene symbol using the annotation platform. When one probe was matched to the same gene, average gene expression of this gene was calculated.</p>
</sec>
<sec id="S2.SS3">
<title>LASSO Regression Analysis</title>
<p>Patients from GSE21653 set were randomized into internal training dataset and internal validation dataset at a ratio of 3:1. The least absolute shrinkage and selection operator (LASSO) model was used to remove genes of high correlation and a risk model was constructed (<xref ref-type="bibr" rid="B30">Tibshirani, 1997</xref>; <xref ref-type="bibr" rid="B35">Zhou et al., 2019</xref>). A risk score formula was established by integrating gene expression value weighted by their LASSO Cox coefficients. R package &#x201C;glmnet&#x201D; in R 3.5.2 was used to perform LASSO analysis (<xref ref-type="bibr" rid="B29">Tern&#x00E8;s et al., 2016</xref>). Univariate and multivariate Cox regression analysis was used to assess the prognostic value of risk score in entire dataset and external validation dataset. Time-dependent receiver operating characteristic (tROC) curves were used to compare the prediction accuracy of risk score with traditional clinicopathological parameters. &#x201C;survivalROC&#x201D; package was used to plot tROC curve and calculate Area under curve (AUC).</p>
</sec>
<sec id="S2.SS4">
<title>Differentially Expressed Genes</title>
<p>In dataset GSE21653, limma package was used to calculate differentially expressed genes between high-risk group and low-risk group patients. <italic>P</italic> value &#x003C;0.05 and absolute fold change greater than 1.5 were defined as DEGs.</p>
</sec>
<sec id="S2.SS5">
<title>Enrichment Analysis</title>
<p>Gene Ontology (GO) was used to annotate biological processes, molecular functions, and cellular components of genes. Kyoto Encyclopedia of Genes and Genomes (KEGG) was used to annotate the gene pathways (<xref ref-type="bibr" rid="B8">Gene Ontology Consortium, 2015</xref>; <xref ref-type="bibr" rid="B13">Kanehisa et al., 2017</xref>). GO and KEGG analysis was performed using clusterProfiler package (<xref ref-type="bibr" rid="B33">Yu et al., 2012</xref>). <italic>P</italic> value &#x003C;0.05 was considered as significant pathways enriched.</p>
</sec>
<sec id="S2.SS6">
<title>PPI Network Construction and Hub Gene Identification</title>
<p>STRING<sup><xref ref-type="fn" rid="footnote4">4</xref></sup> website was used to discover known and predicted protein&#x2013;protein interactions, as well as to construct a PPI network. The Cytoscape software was then employed to visualize the interactive relationship of the overlapped genes.</p>
</sec>
<sec id="S2.SS7">
<title>Weighted Correlation Network Analysis</title>
<p>Weighted Correlation Network Analysis (WGCNA) was performed to find modules of highly correlated genes using WGCNA package (<xref ref-type="bibr" rid="B18">Langfelder and Horvath, 2008</xref>). A One-step network construction was used to construct network and modules were identified. Eigengenes were correlated with external traits to identify modules that are significantly associated with the measured clinical traits. A scatterplot of Gene Significance (GS) versus Module Membership (MM) in different modules was plotted to show the correlation of GS and MM.</p>
</sec>
<sec id="S2.SS8">
<title>Statistical Analysis</title>
<p>Survival analysis was evaluated using Kaplan&#x2013;Meier analysis with the log-rank test. <italic>P</italic> value &#x003C;0.05 was defined as statistically significant. The time-dependent AUC value was calculated by the survivalROC package.</p>
</sec>
</sec>
<sec id="S3">
<title>Results</title>
<sec id="S3.SS1">
<title>Identification of Functional Genomic Genes in Breast Cancer</title>
<p>The flowchart of analysis is shown in <xref ref-type="fig" rid="F1">Figure 1</xref>. A total of 28 cell lines of breast cancer have dependence scores on the Depmap website. Genes with dependence score less than &#x2212;0.5 in all breast cancer cell lines were overlapped with upregulated genes in TCGA and 86 genes were discovered. Meanwhile, genes with dependence score greater than 0.5 in all breast cancer cell lines were overlapped with downregulated genes in TCGA and none of the genes were overlapped (<xref ref-type="fig" rid="F2">Figure 2A</xref>). These 86 genes were defined as oncogenes. The dependence scores of oncogenes are shown in <xref ref-type="fig" rid="F2">Figure 2B</xref> and expression of these genes in TCGA are shown in <xref ref-type="fig" rid="F2">Figure 2C</xref>. PPI network revealed there contains 1117 interactions among these proteins (<xref ref-type="fig" rid="F2">Figure 2D</xref>). Overall, the mutation rate of these genes was low, and INTS7 had the highest mutation rate of 0.8% (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figure 1</xref>). KEGG analysis demonstrated that these oncogenes were enriched in pathways including cell cycle, DNA replication, oocyte meiosis, and nucleotide excision repair gene (<xref ref-type="fig" rid="F2">Figure 2E</xref>). In GO analysis, the top three pathways enriched were ATP binding, adenyl ribonucleotide binding, and adenyl nucleotide binding (<xref ref-type="fig" rid="F2">Figure 2F</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p>Flowchart of the entire analysis.</p></caption>
<graphic xlink:href="fcell-09-646774-g001.tif"/>
</fig>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p>Identification of oncogenes from TCGA and Depmap dataset. <bold>(A)</bold> Overlapped genes between TCGA and Depmap dataset. <bold>(B)</bold> The dependence score of 86 oncogenes in breast cancer cell lines. <bold>(C)</bold> The differential expression of the 86 genes in TCGA dataset between tumor and normal. <bold>(D)</bold> The PPI network of the 86 genes. <bold>(E)</bold> KEGG analysis of 86 genes. <bold>(F)</bold> GO analysis of 86 genes.</p></caption>
<graphic xlink:href="fcell-09-646774-g002.tif"/>
</fig>
</sec>
<sec id="S3.SS2">
<title>Gene Signature Construction and Validation</title>
<p>A total of 51 genes were screened out by Lasso regression model, and a risk formula was constructed. The coefficients are listed in <xref ref-type="supplementary-material" rid="SM1">Supplementary Table 1</xref>. The median risk score 2.36 was used as cut-off value to divide patients into high-risk and low-risk group in internal training dataset and the same cut-off was also used in validation dataset. Patients from the high-risk group had significantly shorter median RFS of 5.52 years compared with patients from the low-risk group in internal training dataset (<xref ref-type="fig" rid="F3">Figure 3A</xref>, <italic>p</italic> &#x003C; 0.001, HR: 2.88, 95% CI: 1.72&#x2013;4.82). This was validated in internal and external validation dataset. As expected, patients with high risk had poorer RFS compared with patients in low-risk group in internal validation dataset (<xref ref-type="fig" rid="F3">Figure 3B</xref>, <italic>p</italic> &#x003C; 0.001, HR: 10.54, 95% CI:1.38&#x2013;80.79), entire train dataset (<xref ref-type="fig" rid="F3">Figure 3D</xref>, <italic>p</italic> &#x003C; 0.001, HR: 3.28, 95% CI: 2.00&#x2013;5.36), and external validation dataset (<xref ref-type="fig" rid="F3">Figure 3E</xref>, <italic>p</italic> &#x003C; 0.001, HR: 8.39, 95% CI: 2.65&#x2013;26.48). Cut-off calculated by ROC curve was used and 2.68 was used as a cut-off to separate patients into different risks. Similarly, both in the entire dataset and validation dataset, there was statistical significance between high-risk and low-risk groups (<xref ref-type="supplementary-material" rid="FS2">Supplementary Figure 2</xref>). For 3-year tROC curves, AUC area was 0.682, 0.812, 0.702, and 0.756 for internal train, internal validation, entire train, and external validation dataset (<xref ref-type="fig" rid="F3">Figure 3C</xref>). For 5-year tROC curves, AUC area was 0.767, 0.761,0.764, and 0.733 for internal train, internal validation, entire train, and external validation dataset, respectively (<xref ref-type="fig" rid="F3">Figure 3F</xref>). The distribution of risk scores of different risk groups are shown in risk plots (<xref ref-type="supplementary-material" rid="FS3">Supplementary Figure 3</xref>). After adjustment of clinicopathological variables, Cox regression demonstrated that the risk score was an independent prognostic signature in the entire train set (<xref ref-type="fig" rid="F4">Figures 4A,B</xref>, <italic>p</italic> &#x003C; 0.001, HR: 3.24, 95% CI: 2.22&#x2013;4.74) and external validation set (<xref ref-type="fig" rid="F4">Figures 4C,D</xref>, <italic>p</italic> &#x003C; 0.001, HR: 3.18, 95% CI: 2.18&#x2013;4.66). Stratified analysis suggested that the signature was clinically significant in stage I + II, stage III + IV cases (<xref ref-type="fig" rid="F5">Figures 5A&#x2013;D</xref>). In both luminal and HER2 amplification groups, RFS of the high-risk group was also worse than that of the low-risk group in validation dataset (<xref ref-type="supplementary-material" rid="FS4">Supplementary Figure 4</xref>, luminal group: <italic>p</italic> &#x003C; 0.0002, HER2 amplification group: <italic>p</italic> = 0.02). A total of 45 patients were included in the basal group and only one patient was included in the low-risk group, so basal cohort with more patients were needed to validate the performance of this signature (<italic>p</italic> = 0.6). Stratified analysis was done in dataset GSE20685 between patients with chemotherapy and without chemotherapy. In patients receiving chemotherapy, RFS of high-risk group was worse than that of low-risk group (<xref ref-type="supplementary-material" rid="FS5">Supplementary Figure 5</xref>, <italic>p</italic> &#x003C; 0.0003). In patients without therapy, the RFS of high-risk group was worse than that of low-risk group, but there was no statistical significance (<italic>p</italic> = 0.1). Meanwhile, our signature outperformed age, stage, and PAM50 subtype in both datasets (<xref ref-type="fig" rid="F6">Figure 6</xref>). For 3-year tROC curves, AUC area was 0.693, 0.538, 0.479, and 0.475 for risk score, age, stage, and PAM50 subtype in entire dataset (<xref ref-type="fig" rid="F6">Figure 6A</xref>). For 5-year tROC curves, AUC area was 0.754, 0.521, 0.450, and 0.456 for risk score, age, stage, and PAM50 subtype in entire dataset (<xref ref-type="fig" rid="F6">Figure 6B</xref>). For 3-year tROC curves, AUC area was 0.756, 0.440, 0.721, and 0.596 for risk score, age, stage, and PAM50 subtype in external validation dataset (<xref ref-type="fig" rid="F6">Figure 6C</xref>). For 5-year tROC curves, AUC area was 0.733, 0.410, 0.697, and 0.566 for risk score, age, stage, and PAM50 subtype in external validation dataset (<xref ref-type="fig" rid="F6">Figure 6D</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p>Kaplan&#x2013;Meier plot and AUC curve of discovery and validation cohort based on gene signature. <bold>(A)</bold> Kaplan&#x2013;Meier plot of the internal train cohort. <bold>(B)</bold> Kaplan&#x2013;Meier plot of the internal validation cohort. <bold>(C)</bold> AUC area of tROC curve of 3-year survival. <bold>(D)</bold> Kaplan&#x2013;Meier plot of the entire cohort. <bold>(E)</bold> Kaplan&#x2013;Meier plot of the external validation cohort. <bold>(F)</bold> AUC area of tROC curve of 5-year survival.</p></caption>
<graphic xlink:href="fcell-09-646774-g003.tif"/>
</fig>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption><p>Univariate and multivariate Cox regression analyses of the entire train and validation cohort. <bold>(A)</bold> Univariate Cox regression analysis in the entire cohort. <bold>(B)</bold> Parameters significant in univariate Cox regression were included in multivariate Cox regression analysis in the entire cohort. <bold>(C)</bold> Univariate Cox regression analysis in the external validation cohort. <bold>(D)</bold> Parameters significant in univariate Cox regression were included in multivariate Cox regression analysis in external validation cohort.</p></caption>
<graphic xlink:href="fcell-09-646774-g004.tif"/>
</fig>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption><p>Kaplan&#x2013;Meier plot of risk score in different subtypes. Kaplan&#x2013;Meier plot of risk score in stage I&#x2013;II <bold>(A)</bold> and stage III&#x2013;IV <bold>(B)</bold> in the entire dataset. Kaplan&#x2013;Meier plot of risk score in stage I&#x2013;II <bold>(C)</bold> and stage III&#x2013;IV <bold>(D)</bold> in external validation dataset.</p></caption>
<graphic xlink:href="fcell-09-646774-g005.tif"/>
</fig>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption><p>AUCs of tROC curve for clinicopathologic parameters and risk score. <bold>(A)</bold> tROC curves of 3-year survival for clinicopathologic parameters and risk score in the entire train dataset. <bold>(B)</bold> tROC curves of 5-year survival for clinicopathologic parameters and risk score in the entire train dataset. <bold>(C)</bold> tROC curves of 3-year survival for clinicopathologic parameters and risk score in the validation dataset. <bold>(D)</bold> tROC curves of 5-year survival for clinicopathologic parameters and risk score in the validation dataset.</p></caption>
<graphic xlink:href="fcell-09-646774-g006.tif"/>
</fig>
</sec>
<sec id="S3.SS3">
<title>DEGs Between High-Risk and Low-Risk Groups</title>
<p>Differentially expressed genes were calculated between high-risk and low-risk groups in GSE21653 dataset. A total of 398 were identified, among which 285 genes were upregulated and 113 genes were downregulated (<xref ref-type="fig" rid="F7">Figures 7A,B</xref>). Downregulated genes were only enriched in PPAR signaling pathway (<xref ref-type="fig" rid="F7">Figure 7C</xref>), whereas upregulated genes were involved in cell cycle, oocyte meiosis, chemokine signaling pathway in KEGG analysis, and in identical protein binding, tubulin binding, and microtubule binding in GO analysis (<xref ref-type="fig" rid="F7">Figures 7D,E</xref>). Interestingly, both in our signature and DEGs, cell cycle and oocyte meiosis were both enriched, indicating cell cycle was an important way regulating cell viability.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption><p>Difference between high risk and low risk. <bold>(A)</bold> Differentially expressed genes in high-risk and low-risk group. <bold>(B)</bold> Heatmap of differentially expressed genes in high-risk and low-risk group. <bold>(C)</bold> KEGG analysis of downregulated genes. <bold>(D)</bold> KEGG analysis of upregulated genes. <bold>(E)</bold> GO analysis of upregulated genes.</p></caption>
<graphic xlink:href="fcell-09-646774-g007.tif"/>
</fig>
</sec>
<sec id="S3.SS4">
<title>WGCNA</title>
<p>WGCNA was performed in GSE21653 dataset to identify hub genes. Soft threshold power of 5 was selected to ensure a scale-free network (<xref ref-type="fig" rid="F8">Figure 8A</xref>). A total of 37 clusters were clustered using cut height 0.25 (<xref ref-type="fig" rid="F8">Figure 8B</xref>). Several modules were correlated with high-risk group (<xref ref-type="fig" rid="F8">Figure 8C</xref>), including light yellow module (correlation parameter = 0.68, <italic>p</italic> &#x003C; 0.001), red module (correlation parameter = 0.5, <italic>p</italic> &#x003C; 0.001), and brown module (correlation parameter = 0.56, <italic>p</italic> &#x003C; 0.001, <xref ref-type="fig" rid="F8">Figures 8D&#x2013;F</xref>). Upregulated DEGs from GSE21653 dataset, genes from three modules, and 86 oncogenes were overlapped and 25 genes were shared in these three groups (<xref ref-type="fig" rid="F8">Figure 8G</xref>). Enrichment analysis showed that cell cycle, progesterone-mediated oocyte maturation, and oocyte meiosis pathways were the top three pathways (<xref ref-type="fig" rid="F8">Figure 8H</xref>). In GO analysis, the top three items enriched in these 25 genes were enzyme binding, ATP binding, and adenyl ribonucleotide binding (<xref ref-type="fig" rid="F8">Figure 8I</xref>). Of the 25 overlapped genes, 9 genes (CDC6, MCM2, MCM4, CDC20, CDK1, BUB1B, PLK1, CCNA2, GINS1) were enriched in cell cycle pathway. Similarly, upregulated DEGs from GSE21653 dataset, genes from three modules, and 51 oncogenes were overlapped and 25 genes were shared in these three groups (<xref ref-type="supplementary-material" rid="FS6">Supplementary Figure 6</xref>). A total of 13 genes were overlapped and cell cycle was still the main pathway regulated by these 13 genes. Six genes (CDC6 MCM4 CDK1 BUB1B PLK1 CCNA2) were enriched in cell cycle pathway.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption><p>WGCNA analysis related with high risk. <bold>(A)</bold> Analysis of scale-free fit index for various soft threshold powers. <bold>(B)</bold> Co-expression network modules for mRNA. <bold>(C)</bold> Heatmap of trait correlation with tamoxifen resistance. <bold>(D)</bold> Scatter plots of module membership in red module and gene significance. <bold>(E)</bold> Scatter plots of module membership in brown module and gene significance. <bold>(F)</bold> Scatter plots of module membership in light yellow module and gene significance. <bold>(G)</bold> Venn diagram of overlapped genes among 86 oncogenes, DEGs between high-risk and low-risk patients and WGCNA modules. <bold>(H)</bold> KEGG analysis of overlapped genes. <bold>(I)</bold> GO analysis of overlapped genes.</p></caption>
<graphic xlink:href="fcell-09-646774-g008.tif"/>
</fig>
</sec>
</sec>
<sec id="S4">
<title>Discussion</title>
<p>Breast cancer poses a great threat to women&#x2019;s health. Reliable targeted therapy provides prospects for improving the survival of breast cancer. The CRISPR-cas9 screening serves as a cornerstone and is an outstanding way to systematically identify synthetic-lethal genes (<xref ref-type="bibr" rid="B3">Dhanjal et al., 2017</xref>). In the current study, we integrated CRISPR-cas9 screening results of breast cancer from DepMap with TCGA dataset, and identified 86 oncogenes that were overexpressed and have a lethal effect on breast cancer. Enrichment analysis revealed that these genes were enriched in cell cycle. Moreover, we established a gene signature screened from 86 genes, and this signature could divide patients into high risk and low risk. Interestingly, cell cycle pathway also ranked the first when we analyzed DEGs between high-risk and low-risk group and genes. Overlap among the 86 oncogenes, DEGs, and WGCNA analysis highlight the cell cycle pathways as well, indicating its importance to breast cancer viability.</p>
<p>In our study, 9 cell cycle related genes mainly involved in G1/S and G2/M phases, and researches on mechanism of these genes have been conducted. MCM2 and MCM4 genes are members of minichromosome maintenance (MCM) protein complex. As a crucial element of the pre-replication complex (pre-RC), they regulate the helicase activity and the formation of the replication forks. Meanwhile, they play an important role in the initiation of DNA replication and unwinding of the DNA strands in the G1 to S transition phase (<xref ref-type="bibr" rid="B6">Forsburg, 2004</xref>). High expression of MCM2 was associated with poor survival in breast cancer patients (<xref ref-type="bibr" rid="B23">Samad et al., 2020</xref>). In our analysis, we identified that MCM2 and MCM4 are vital to the survival of breast cancer. CDC6 plays an important role in DNA replication and cells could not initiate DNA replication without CDC6 (<xref ref-type="bibr" rid="B2">Borlado and M&#x00E9;ndez, 2008</xref>). CDC6 helps MCM proteins load onto origins of replication and promotes them to associate with the chromatin. GINS1 also had a vital effect on G1/S transition by tightly interacting with DNA polymerase &#x03B5; (Pol &#x03B5;) and participating in DNA replication (<xref ref-type="bibr" rid="B28">Takayama et al., 2003</xref>). The rest of the genes mainly had critical function in G2 to M transition. CDK1 is one of the most important proteins that regulate cell cycle progression via associating with cyclin B1 and promote G2 to M transition. High expression of CDK1 was reported in breast cancer compared with normal tissue (<xref ref-type="bibr" rid="B1">Barrett et al., 2002</xref>). CDC20 is co-activator of anaphase promoting complex (APC) which is a complex E3 ubiquitin ligase (<xref ref-type="bibr" rid="B5">Foe and Toczyski, 2011</xref>). APC<sup><italic>Cdc</italic>20</sup> destructs critical cell cycle regulators such as cyclin B, allowing cells to progress from the metaphase to anaphase transition (<xref ref-type="bibr" rid="B15">Kim and Yu, 2011</xref>). CDC20 was reported higher expressed in breast cancer and functions as an oncogene, which was also validated in our analysis (<xref ref-type="bibr" rid="B34">Yuan et al., 2006</xref>). BUB1B, which blocks the activation of APC<sup><italic>Cdc</italic>20</sup>, is the central component of the mitotic checkpoint for spindle assembly, and it was proved overexpressed in breast cancer and acts as a oncogene (<xref ref-type="bibr" rid="B16">Koyuncu et al., 2020</xref>). PLK1, as a member of polo-like kinase family, is involved in mitotic entry, centrosome maturation, spindle assembly, and cytokinesis process (<xref ref-type="bibr" rid="B9">Golsteyn et al., 1995</xref>; <xref ref-type="bibr" rid="B7">Garc&#x00ED;a et al., 2020</xref>). Results from CRISPR-cas9 screening suggested that knocking out these genes leads to cell death in breast cancer of all subtypes, and inhibitors targeting these genes may be potential therapeutic strategies for breast cancer. Furthermore, upregulation of these genes in breast cancer indicates that they may be good candidates for drug development.</p>
<p>Previous studies constructed a prognostic signature mainly based on the gene expression, while we integrated functional genomic screening with gene expression in the current study. Our gene signature could divide patients into high risk and low risk regardless of the tumor stage. For patients with high risk, appropriate target agent may be prescribed to improve patients&#x2019; outcome. The prediction accuracy of our signature was better than classic clinicopathologic parameters such as tumor stage or PAM50 subtype. This signature was the only independent prognostic parameter in multivariate analysis, although subtypes and stage were widely used in clinical practice.</p>
<p>In conclusion, our research systematically studied genes vulnerable to cell viability and cell cycle is a vital pathway to this process. Functional genomic screening was integrated into our gene signature to predict the prognosis of breast cancer, which outperformed classical clinicopathological parameters in prediction accuracy. These cell cycle&#x2013;related genes may serve as targets for breast cancer therapy.</p>
</sec>
<sec id="S5">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">Supplementary Material</xref>, further inquiries can be directed to the corresponding author/s.</p>
</sec>
<sec id="S6">
<title>Author Contributions</title>
<p>XS participated in all experimental work and drafted the manuscript. XC and KS designed the article. ZW collected the data. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>We would like to acknowledge the GEO database developed by the National Institutes of Health (NIH). We appreciate the financial support by the National Natural Science Foundation of China (grant nos. 81772797 and 82002773); Shanghai Municipal Education Commission&#x2014;Gaofeng Clinical Medicine Grant Support (20172007); and Ruijin Hospital, Shanghai Jiao Tong University School of Medicine&#x2014;&#x201C;Guangci Excellent Youth Training Program&#x201D; (GCQN-2017-A18). All these financial sponsors had no role in the study design, collection, analysis, or interpretation of data.</p>
</ack>
<sec id="S8" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcell.2021.646774/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcell.2021.646774/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table_1.DOCX" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image_1.TIF" id="FS1" mimetype="image/tiff" xmlns:xlink="http://www.w3.org/1999/xlink">
<label>Supplementary Figure 1</label>
<caption><p>Mutation rate of 86 genes in TCGA dataset.</p></caption>
</supplementary-material>
<supplementary-material xlink:href="Image_2.TIF" id="FS2" mimetype="image/tiff" xmlns:xlink="http://www.w3.org/1999/xlink">
<label>Supplementary Figure 2</label>
<caption><p>Kaplan&#x2013;Meier plot of discovery and validation cohort based on gene signature using cut-off from ROC curve. <bold>(A)</bold> Kaplan&#x2013;Meier plot of the internal train cohort. <bold>(B)</bold> Kaplan&#x2013;Meier plot of the internal validation cohort. <bold>(C)</bold> Kaplan&#x2013;Meier plot of the entire cohort. <bold>(D)</bold> Kaplan&#x2013;Meier plot of the external validation cohort.</p></caption>
</supplementary-material>
<supplementary-material xlink:href="Image_3.TIF" id="FS3" mimetype="image/tiff" xmlns:xlink="http://www.w3.org/1999/xlink">
<label>Supplementary Figure 3</label>
<caption><p>Risk plot of the discovery and validation cohort. <bold>(A)</bold> Risk score distribution of patients in the prognostic model in the discovery cohort. <bold>(B)</bold> Relationship between the survival time and risk score rank in the discovery cohort. <bold>(C)</bold> Risk score distribution of patients in the prognostic model in the validation dataset. <bold>(D)</bold> Relationship between the survival time and risk score rank in the validation cohort.</p></caption>
</supplementary-material>
<supplementary-material xlink:href="Image_4.TIF" id="FS4" mimetype="image/tiff" xmlns:xlink="http://www.w3.org/1999/xlink">
<label>Supplementary Figure 4</label>
<caption><p>Kaplan&#x2013;Meier plot of risk score in different subtypes. Kaplan&#x2013;Meier plot of risk score in luminal <bold>(A)</bold> and HER2 <bold>(B)</bold> subtypes in GSE20685 dataset.</p></caption>
</supplementary-material>
<supplementary-material xlink:href="Image_5.TIF" id="FS5" mimetype="image/tiff" xmlns:xlink="http://www.w3.org/1999/xlink">
<label>Supplementary Figure 5</label>
<caption><p>Kaplan&#x2013;Meier plot of risk score in different chemotherapy groups. Kaplan&#x2013;Meier plot of risk score in patients with chemotherapy <bold>(A)</bold> and without chemotherapy <bold>(B)</bold> in GSE20685 dataset.</p></caption>
</supplementary-material>
<supplementary-material xlink:href="Image_6.TIF" id="FS6" mimetype="image/tiff" xmlns:xlink="http://www.w3.org/1999/xlink">
<label>Supplementary Figure 6</label>
<caption><p>Overlapped genes between three groups. <bold>(A)</bold> Venn diagram of overlapped genes among 51oncogenes, DEGs between high-risk and low-risk patients, and WGCNA modules. <bold>(B)</bold> GO analysis of overlapped genes. <bold>(C)</bold> KEGG analysis of overlapped genes.</p></caption>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname> <given-names>K. L.</given-names></name> <name><surname>Demiranda</surname> <given-names>D.</given-names></name> <name><surname>Katula</surname> <given-names>K. S.</given-names></name></person-group> (<year>2002</year>). <article-title>Cyclin b1 promoter activity and functional cdk1 complex formation in G1 phase of human breast cancer cells.</article-title> <source><italic>Cell Biol. Int.</italic></source> <volume>26</volume> <fpage>19</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1006/cbir.2001.0817</pub-id> <pub-id pub-id-type="pmid">11779217</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borlado</surname> <given-names>L. R.</given-names></name> <name><surname>M&#x00E9;ndez</surname> <given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>CDC6: from DNA replication to cell cycle checkpoints and oncogenesis.</article-title> <source><italic>Carcinogenesis</italic></source> <volume>29</volume> <fpage>237</fpage>&#x2013;<lpage>243</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/bgm268</pub-id> <pub-id pub-id-type="pmid">18048387</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhanjal</surname> <given-names>J. K.</given-names></name> <name><surname>Radhakrishnan</surname> <given-names>N.</given-names></name> <name><surname>Sundar</surname> <given-names>D.</given-names></name></person-group> (<year>2017</year>). <article-title>Identifying synthetic lethal targets using CRISPR/Cas9 system.</article-title> <source><italic>Methods</italic></source> <volume>131</volume> <fpage>66</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymeth.2017.07.007</pub-id> <pub-id pub-id-type="pmid">28710008</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doudna</surname> <given-names>J. A.</given-names></name> <name><surname>Charpentier</surname> <given-names>E.</given-names></name></person-group> (<year>2014</year>). <article-title>Genome editing. The new frontier of genome engineering with CRISPR-Cas9.</article-title> <source><italic>Science</italic></source> <volume>346</volume>:<issue>1258096</issue>. <pub-id pub-id-type="doi">10.1126/science.1258096</pub-id> <pub-id pub-id-type="pmid">25430774</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foe</surname> <given-names>I.</given-names></name> <name><surname>Toczyski</surname> <given-names>D.</given-names></name></person-group> (<year>2011</year>). <article-title>Structural biology: a new look for the APC.</article-title> <source><italic>Nature</italic></source> <volume>470</volume> <fpage>182</fpage>&#x2013;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1038/470182a</pub-id> <pub-id pub-id-type="pmid">21307929</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Forsburg</surname> <given-names>S. L.</given-names></name></person-group> (<year>2004</year>). <article-title>Eukaryotic MCM proteins: beyond replication initiation.</article-title> <source><italic>Microbiol. Mol. Biol. Rev.</italic></source> <volume>68</volume> <fpage>109</fpage>&#x2013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1128/mmbr.68.1.109-131.2004</pub-id> <pub-id pub-id-type="pmid">15007098</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x00ED;a</surname> <given-names>I. A.</given-names></name> <name><surname>Garro</surname> <given-names>C.</given-names></name> <name><surname>Fernandez</surname> <given-names>E.</given-names></name> <name><surname>Soria</surname> <given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Therapeutic opportunities for PLK1 inhibitors: spotlight on BRCA1-deficiency and triple negative breast cancers.</article-title> <source><italic>Mutat. Res.</italic></source> <volume>821</volume>:<issue>111693</issue>. <pub-id pub-id-type="doi">10.1016/j.mrfmmm.2020.111693</pub-id> <pub-id pub-id-type="pmid">32172132</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><collab>Gene Ontology Consortium</collab> (<year>2015</year>). <article-title>Gene ontology consortium: going forward.</article-title> <source><italic>Nucleic Acids Res.</italic></source> <volume>43</volume> <fpage>D1049</fpage>&#x2013;<lpage>D1056</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku1179</pub-id> <pub-id pub-id-type="pmid">25428369</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Golsteyn</surname> <given-names>R. M.</given-names></name> <name><surname>Mundt</surname> <given-names>K. E.</given-names></name> <name><surname>Fry</surname> <given-names>A. M.</given-names></name> <name><surname>Nigg</surname> <given-names>E. A.</given-names></name></person-group> (<year>1995</year>). <article-title>Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function.</article-title> <source><italic>J. Cell Biol.</italic></source> <volume>129</volume> <fpage>1617</fpage>&#x2013;<lpage>1628</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.129.6.1617</pub-id> <pub-id pub-id-type="pmid">7790358</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname> <given-names>D.</given-names></name> <name><surname>Weinberg</surname> <given-names>R. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Hallmarks of cancer: the next generation.</article-title> <source><italic>Cell</italic></source> <volume>144</volume> <fpage>646</fpage>&#x2013;<lpage>674</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id> <pub-id pub-id-type="pmid">21376230</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ingham</surname> <given-names>M.</given-names></name> <name><surname>Schwartz</surname> <given-names>G. K.</given-names></name></person-group> (<year>2017</year>). <article-title>Cell-Cycle therapeutics come of age.</article-title> <source><italic>J. Clin. Oncol.</italic></source> <volume>35</volume> <fpage>2949</fpage>&#x2013;<lpage>2959</lpage>. <pub-id pub-id-type="doi">10.1200/jco.2016.69.0032</pub-id> <pub-id pub-id-type="pmid">28580868</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joung</surname> <given-names>J.</given-names></name> <name><surname>Konermann</surname> <given-names>S.</given-names></name> <name><surname>Gootenberg</surname> <given-names>J. S.</given-names></name> <name><surname>Abudayyeh</surname> <given-names>O. O.</given-names></name> <name><surname>Platt</surname> <given-names>R. J.</given-names></name> <name><surname>Brigham</surname> <given-names>M. D.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening.</article-title> <source><italic>Nat. Protoc.</italic></source> <volume>12</volume> <fpage>828</fpage>&#x2013;<lpage>863</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2017.016</pub-id> <pub-id pub-id-type="pmid">28333914</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname> <given-names>M.</given-names></name> <name><surname>Furumichi</surname> <given-names>M.</given-names></name> <name><surname>Tanabe</surname> <given-names>M.</given-names></name> <name><surname>Sato</surname> <given-names>Y.</given-names></name> <name><surname>Morishima</surname> <given-names>K.</given-names></name></person-group> (<year>2017</year>). <article-title>KEGG: new perspectives on genomes, pathways, diseases and drugs.</article-title> <source><italic>Nucleic Acids Res.</italic></source> <volume>45</volume> <fpage>D353</fpage>&#x2013;<lpage>D361</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkw1092</pub-id> <pub-id pub-id-type="pmid">27899662</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kastan</surname> <given-names>M. B.</given-names></name> <name><surname>Bartek</surname> <given-names>J.</given-names></name></person-group> (<year>2004</year>). <article-title>Cell-cycle checkpoints and cancer.</article-title> <source><italic>Nature</italic></source> <volume>432</volume> <fpage>316</fpage>&#x2013;<lpage>323</lpage>. <pub-id pub-id-type="doi">10.1038/nature03097</pub-id> <pub-id pub-id-type="pmid">15549093</pub-id></citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>S.</given-names></name> <name><surname>Yu</surname> <given-names>H.</given-names></name></person-group> (<year>2011</year>). <article-title>Mutual regulation between the spindle checkpoint and APC/C.</article-title> <source><italic>Semin. Cell Dev. Biol.</italic></source> <volume>22</volume> <fpage>551</fpage>&#x2013;<lpage>558</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcdb.2011.03.008</pub-id> <pub-id pub-id-type="pmid">21439394</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koyuncu</surname> <given-names>D.</given-names></name> <name><surname>Sharma</surname> <given-names>U.</given-names></name> <name><surname>Goka</surname> <given-names>E. T.</given-names></name> <name><surname>Lippman</surname> <given-names>M. E.</given-names></name></person-group> (<year>2020</year>). <article-title>Spindle assembly checkpoint gene BUB1B is essential in breast cancer cell survival.</article-title> <source><italic>Breast Cancer Res. Treat.</italic></source> <volume>185</volume> <fpage>331</fpage>&#x2013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1007/s10549-020-05962-2</pub-id> <pub-id pub-id-type="pmid">33130993</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurata</surname> <given-names>M.</given-names></name> <name><surname>Yamamoto</surname> <given-names>K.</given-names></name> <name><surname>Moriarity</surname> <given-names>B. S.</given-names></name> <name><surname>Kitagawa</surname> <given-names>M.</given-names></name> <name><surname>Largaespada</surname> <given-names>D. A.</given-names></name></person-group> (<year>2018</year>). <article-title>CRISPR/Cas9 library screening for drug target discovery.</article-title> <source><italic>J. Hum. Genet.</italic></source> <volume>63</volume> <fpage>179</fpage>&#x2013;<lpage>186</lpage>. <pub-id pub-id-type="doi">10.1038/s10038-017-0376-9</pub-id> <pub-id pub-id-type="pmid">29158600</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langfelder</surname> <given-names>P.</given-names></name> <name><surname>Horvath</surname> <given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>WGCNA: an R package for weighted correlation network analysis.</article-title> <source><italic>BMC Bioinformatics</italic></source> <volume>9</volume>:<issue>559</issue>. <pub-id pub-id-type="doi">10.1186/1471-2105-9-559</pub-id> <pub-id pub-id-type="pmid">19114008</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname> <given-names>S.</given-names></name> <name><surname>Kaldis</surname> <given-names>P.</given-names></name></person-group> (<year>2013</year>). <article-title>Cdks, cyclins and CKIs: roles beyond cell cycle regulation.</article-title> <source><italic>Development</italic></source> <volume>140</volume> <fpage>3079</fpage>&#x2013;<lpage>3093</lpage>. <pub-id pub-id-type="doi">10.1242/dev.091744</pub-id> <pub-id pub-id-type="pmid">23861057</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malumbres</surname> <given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Cyclin-dependent kinases.</article-title> <source><italic>Genome Biol.</italic></source> <volume>15</volume>:<issue>122</issue>. <pub-id pub-id-type="doi">10.1186/gb4184</pub-id> <pub-id pub-id-type="pmid">25180339</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malumbres</surname> <given-names>M.</given-names></name> <name><surname>Barbacid</surname> <given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Cell cycle, CDKs and cancer: a changing paradigm.</article-title> <source><italic>Nat. Rev. Cancer</italic></source> <volume>9</volume> <fpage>153</fpage>&#x2013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1038/nrc2602</pub-id> <pub-id pub-id-type="pmid">19238148</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname> <given-names>R. M.</given-names></name> <name><surname>Bryan</surname> <given-names>J. G.</given-names></name> <name><surname>McFarland</surname> <given-names>J. M.</given-names></name> <name><surname>Weir</surname> <given-names>B. A.</given-names></name> <name><surname>Sizemore</surname> <given-names>A. E.</given-names></name> <name><surname>Xu</surname> <given-names>H.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.</article-title> <source><italic>Nat. Genet.</italic></source> <volume>49</volume> <fpage>1779</fpage>&#x2013;<lpage>1784</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3984</pub-id> <pub-id pub-id-type="pmid">29083409</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samad</surname> <given-names>A.</given-names></name> <name><surname>Haque</surname> <given-names>F.</given-names></name> <name><surname>Nain</surname> <given-names>Z.</given-names></name> <name><surname>Alam</surname> <given-names>R.</given-names></name> <name><surname>Al Noman</surname> <given-names>M. A.</given-names></name> <name><surname>Rahman Molla</surname> <given-names>M. H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Computational assessment of MCM2 transcriptional expression and identification of the prognostic biomarker for human breast cancer.</article-title> <source><italic>Heliyon</italic></source> <volume>6</volume>:<issue>e05087</issue>. <pub-id pub-id-type="doi">10.1016/j.heliyon.2020.e05087</pub-id> <pub-id pub-id-type="pmid">33024849</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schuster</surname> <given-names>A.</given-names></name> <name><surname>Erasimus</surname> <given-names>H.</given-names></name> <name><surname>Fritah</surname> <given-names>S.</given-names></name> <name><surname>Nazarov</surname> <given-names>P. V.</given-names></name> <name><surname>van Dyck</surname> <given-names>E.</given-names></name> <name><surname>Niclou</surname> <given-names>S. P.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>RNAi/CRISPR screens: from a pool to a valid hit.</article-title> <source><italic>Trends Biotechnol.</italic></source> <volume>37</volume> <fpage>38</fpage>&#x2013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibtech.2018.08.002</pub-id> <pub-id pub-id-type="pmid">30177380</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname> <given-names>R. L.</given-names></name> <name><surname>Miller</surname> <given-names>K. D.</given-names></name> <name><surname>Jemal</surname> <given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Cancer statistics, 2020.</article-title> <source><italic>CA Cancer J. Clin.</italic></source> <volume>70</volume> <fpage>7</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21590</pub-id> <pub-id pub-id-type="pmid">31912902</pub-id></citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slamon</surname> <given-names>D. J.</given-names></name> <name><surname>Neven</surname> <given-names>P.</given-names></name> <name><surname>Chia</surname> <given-names>S.</given-names></name> <name><surname>Fasching</surname> <given-names>P. A.</given-names></name> <name><surname>De Laurentiis</surname> <given-names>M.</given-names></name> <name><surname>Im</surname> <given-names>S. A.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Phase III randomized study of Ribociclib and Fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3.</article-title> <source><italic>J. Clin. Oncol.</italic></source> <volume>36</volume> <fpage>2465</fpage>&#x2013;<lpage>2472</lpage>. <pub-id pub-id-type="doi">10.1200/jco.2018.78.9909</pub-id> <pub-id pub-id-type="pmid">29860922</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strzyz</surname> <given-names>P.</given-names></name></person-group> (<year>2016</year>). <article-title>Cell signalling: signalling to cell cycle arrest.</article-title> <source><italic>Nat. Rev. Mol. Cell Biol.</italic></source> <volume>17</volume>:<issue>536</issue>. <pub-id pub-id-type="doi">10.1038/nrm.2016.108</pub-id> <pub-id pub-id-type="pmid">27507208</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takayama</surname> <given-names>Y.</given-names></name> <name><surname>Kamimura</surname> <given-names>Y.</given-names></name> <name><surname>Okawa</surname> <given-names>M.</given-names></name> <name><surname>Muramatsu</surname> <given-names>S.</given-names></name> <name><surname>Sugino</surname> <given-names>A.</given-names></name> <name><surname>Araki</surname> <given-names>H.</given-names></name></person-group> (<year>2003</year>). <article-title>GINS, a novel multiprotein complex required for chromosomal DNA replication in budding yeast.</article-title> <source><italic>Genes Dev.</italic></source> <volume>17</volume> <fpage>1153</fpage>&#x2013;<lpage>1165</lpage>. <pub-id pub-id-type="doi">10.1101/gad.1065903</pub-id> <pub-id pub-id-type="pmid">12730134</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tern&#x00E8;s</surname> <given-names>N.</given-names></name> <name><surname>Rotolo</surname> <given-names>F.</given-names></name> <name><surname>Michiels</surname> <given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Empirical extensions of the lasso penalty to reduce the false discovery rate in high-dimensional Cox regression models.</article-title> <source><italic>Stat. Med.</italic></source> <volume>35</volume> <fpage>2561</fpage>&#x2013;<lpage>2573</lpage>. <pub-id pub-id-type="doi">10.1002/sim.6927</pub-id> <pub-id pub-id-type="pmid">26970107</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tibshirani</surname> <given-names>R.</given-names></name></person-group> (<year>1997</year>). <article-title>The lasso method for variable selection in the Cox model.</article-title> <source><italic>Stat. Med.</italic></source> <volume>16</volume> <fpage>385</fpage>&#x2013;<lpage>395</lpage>.</citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tripathy</surname> <given-names>D.</given-names></name> <name><surname>Im</surname> <given-names>S. A.</given-names></name> <name><surname>Colleoni</surname> <given-names>M.</given-names></name> <name><surname>Franke</surname> <given-names>F.</given-names></name> <name><surname>Bardia</surname> <given-names>A.</given-names></name> <name><surname>Harbeck</surname> <given-names>N.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.</article-title> <source><italic>Lancet Oncol.</italic></source> <volume>19</volume> <fpage>904</fpage>&#x2013;<lpage>915</lpage>. <pub-id pub-id-type="doi">10.1016/s1470-2045(18)30292-4</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsherniak</surname> <given-names>A.</given-names></name> <name><surname>Vazquez</surname> <given-names>F.</given-names></name> <name><surname>Montgomery</surname> <given-names>P. G.</given-names></name> <name><surname>Weir</surname> <given-names>B. A.</given-names></name> <name><surname>Kryukov</surname> <given-names>G.</given-names></name> <name><surname>Cowley</surname> <given-names>G. S.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Defining a cancer dependency map.</article-title> <source><italic>Cell</italic></source> <volume>170</volume> <fpage>564</fpage>-<lpage>576.e516</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.06.010</pub-id> <pub-id pub-id-type="pmid">28753430</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>G.</given-names></name> <name><surname>Wang</surname> <given-names>L. G.</given-names></name> <name><surname>Han</surname> <given-names>Y.</given-names></name> <name><surname>He</surname> <given-names>Q. Y.</given-names></name></person-group> (<year>2012</year>). <article-title>clusterProfiler: an R package for comparing biological themes among gene clusters.</article-title> <source><italic>OMICS</italic></source> <volume>16</volume> <fpage>284</fpage>&#x2013;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id> <pub-id pub-id-type="pmid">22455463</pub-id></citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname> <given-names>B.</given-names></name> <name><surname>Xu</surname> <given-names>Y.</given-names></name> <name><surname>Woo</surname> <given-names>J. H.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Bae</surname> <given-names>Y. K.</given-names></name> <name><surname>Yoon</surname> <given-names>D. S.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability.</article-title> <source><italic>Clin. Cancer Res.</italic></source> <volume>12</volume> <fpage>405</fpage>&#x2013;<lpage>410</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-05-0903</pub-id> <pub-id pub-id-type="pmid">16428479</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Z. R.</given-names></name> <name><surname>Wang</surname> <given-names>W. W.</given-names></name> <name><surname>Li</surname> <given-names>Y.</given-names></name> <name><surname>Jin</surname> <given-names>K. R.</given-names></name> <name><surname>Wang</surname> <given-names>X. Y.</given-names></name> <name><surname>Wang</surname> <given-names>Z. W.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>In-depth mining of clinical data: the construction of clinical prediction model with R.</article-title> <source><italic>Ann. Transl. Med.</italic></source> <volume>7</volume>:<issue>796</issue>. <pub-id pub-id-type="doi">10.21037/atm.2019.08.63</pub-id> <pub-id pub-id-type="pmid">32042812</pub-id></citation></ref>
</ref-list><fn-group>
<fn id="footnote1">
<label>1</label>
<p><ext-link ext-link-type="uri" xlink:href="https://depmap.org/portal/download/">https://depmap.org/portal/download/</ext-link></p></fn>
<fn id="footnote2">
<label>2</label>
<p><ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</ext-link></p></fn>
<fn id="footnote3">
<label>3</label>
<p><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</ext-link></p></fn>
<fn id="footnote4">
<label>4</label>
<p><ext-link ext-link-type="uri" xlink:href="http://string-db.org">http://string-db.org</ext-link></p></fn>
</fn-group>
</back>
</article>